|
|
| | 5-(4-Methylpiperazin-1-yl)pyridin-2-amine Basic information |
| Product Name: | 5-(4-Methylpiperazin-1-yl)pyridin-2-amine | | Synonyms: | 1-METHYL-4-(6-AMINOPYRIDIN-3-YL)PIPERAZINE;5-(4-Methyl-piperazin-1-yl)-pyridin-2-ylamine;5-(4-Methylpiperazin-1-yl);2-PyridinaMine, 5-(4-Methyl-1-piperazinyl)-;2-Amino-5-(4-methyl-1-piperazinyl)pyridine;2-Amino-5-(N-methylpiperazin-1-yl)pyridine;-4-(6-aminopyridin-3-yL;5-(4-Methyl-1-piperazinyl)-2-pyridinamine | | CAS: | 571189-49-6 | | MF: | C10H16N4 | | MW: | 192.26 | | EINECS: | | | Product Categories: | | | Mol File: | 571189-49-6.mol |  |
| | 5-(4-Methylpiperazin-1-yl)pyridin-2-amine Chemical Properties |
| Melting point | 148 °C | | Boiling point | 368.1±42.0 °C(Predicted) | | density | 1.142±0.06 g/cm3(Predicted) | | storage temp. | Keep in dark place,Inert atmosphere,Room temperature | | solubility | Acetonitrile (Slightly), Chloroform (Slightly), Water (Slightly) | | pka | 7.41±0.42(Predicted) | | form | powder to crystal | | color | Light yellow to Brown | | Stability: | Hygroscopic | | InChI | InChI=1S/C10H16N4/c1-13-4-6-14(7-5-13)9-2-3-10(11)12-8-9/h2-3,8H,4-7H2,1H3,(H2,11,12) | | InChIKey | QDMPMBFLXOWHRY-UHFFFAOYSA-N | | SMILES | C1(N)=NC=C(N2CCN(C)CC2)C=C1 |
| Hazard Codes | Xn | | Risk Statements | 22 | | HS Code | 2933399990 |
| | 5-(4-Methylpiperazin-1-yl)pyridin-2-amine Usage And Synthesis |
| Description | 5-(4-Methylpiperazin-1-yl)pyridin-2-amine is a pharmaceutical intermediate compound that can be used to prepare trilaciclib. Trilaciclib is the first intravenous CDK4/6 inhibitor approved by the FDA for reducing the risk of bone marrow suppression (i.e. decreased red blood cells, white blood cells, and platelets) in adult patients with small cell lung cancer (SCLC) caused by specific chemotherapy drugs. | | Chemical Properties | Light yellow to Brown powder to crystal. | | Uses | 5-(4-Methylpiperazin-1-yl)pyridin-2-amine can be used for chemical mechanical planarization for tungsten-containing substrates. | | Synthesis | General procedure for the synthesis of 1-methyl-4-(6-aminopyridin-3-yl)piperazine from 1-methyl-4-(6-nitropyridin-3-yl)piperazine: a mixture of 1-methyl-4-(6-nitropyridin-3-yl)piperazine (1.11 g, 5.02 mmol) and 10% Pd/C (110 mg) in methanol (15 mL) was stirred for 5 h at room temperature . Upon completion of the reaction, the catalyst was removed by filtration and the filtrate was concentrated to afford 951 mg (99% yield) of a yellow solid product, 1-methyl-4-(6-aminopyridin-3-yl)piperazine, which could be used in the subsequent reaction without further purification. The 1H NMR (CDCl3) data of the product were as follows: δ 7.78 (d, 1H, J = 3.0 Hz), 7.18 (dd, 1H, J = 3.0, 8.9 Hz), 6.48 (d, 1H, J = 8.9 Hz), 3.08 (dd, 4H, J = 4.9, 4.9 Hz), 2.61 (dd, 4H, J = 4.9, 4.9 Hz) , 2.37 (s, 3H). | | References | [1] Journal of Medicinal Chemistry, 2017, vol. 60, # 5, p. 1892 - 1915
[2] Patent: US2005/38078, 2005, A1. Location in patent: Page/Page column 29
[3] Patent: WO2004/14904, 2004, A1. Location in patent: Page 51
[4] Bioorganic and Medicinal Chemistry, 2015, vol. 23, # 2, p. 348 - 364
[5] Patent: US2017/313683, 2017, A1. Location in patent: Paragraph 0300-0301 |
| | 5-(4-Methylpiperazin-1-yl)pyridin-2-amine Preparation Products And Raw materials |
|